Viridian Therapeutics, Inc.\DE (VRDN) Total Liabilities (2013 - 2026)

Viridian Therapeutics, Inc.\DE's Total Liabilities history runs 14 years deep, the most recent figure standing at $153.0 million for Q1 2026.

• On a quarterly basis, Total Liabilities rose 170.77% year-over-year to $153.0 million in Q1 2026; TTM through Mar 2026 was $153.0 million, a 170.77% increase from a year earlier, with the FY2025 full-year figure at $177.3 million, up 150.48% from the prior year.
• Total Liabilities declined to $153.0 million in Q1 2026 per VRDN's latest filing, from $177.3 million in the prior quarter.
• Across five years, Total Liabilities topped out at $177.3 million in Q4 2025 and bottomed at $16.5 million in Q1 2022.
• The 5-year median for Total Liabilities is $48.4 million (2023), against an average of $61.7 million.
• Across the five-year window, Total Liabilities retreated 1.85% in 2022 and jumped 170.77% in 2026, its largest moves.
• Year by year, Total Liabilities stood at $40.0 million in 2022, then rose by 20.92% to $48.4 million in 2023, then jumped by 46.2% to $70.8 million in 2024, then jumped by 150.48% to $177.3 million in 2025, then retreated by 13.68% to $153.0 million in 2026.
• Per Business Quant, the three latest VRDN Total Liabilities figures stand at $153.0 million (Q1 2026), $177.3 million (Q4 2025), and $74.2 million (Q3 2025).